Clinical Trial Detail

NCT ID NCT01669798
Title BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors AA Secord
Indications

ovarian carcinoma

peritoneal carcinoma

fallopian tube carcinoma

malignant ovarian Brenner tumor

Therapies

Nintedanib

Age Groups: adult

No variant requirements are available.